Evolving pharmacology of orphan GPCRs: IUPHAR Commentary |
| |
Authors: | Anthony P Davenport Anthony J Harmar |
| |
Affiliation: | 1.Clinical Pharmacology Unit, Addenbrooke''s Hospital, University of Cambridge, Cambridge, UK;2.University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK |
| |
Abstract: | The award of the 2012 Nobel Prize in Chemistry to Robert Lefkowitz and Brian Kobilka for their work on the structure and function of GPCRs, spanning a period of more than 20 years from the cloning of the human β2-adrenoceptor to determining the crystal structure of the same protein, has earned both researchers a much deserved place in the pantheon of major scientific discoveries. GPCRs comprise one of the largest families of proteins, controlling many major physiological processes and have been a major focus of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) since its inception in 1987. We report here recent efforts by the British Pharmacological Society and NC-IUPHAR to define the endogenous ligands of ‘orphan’ GPCRs and to place authoritative and accessible information about these crucial therapeutic targets online. |
| |
Keywords: | chemerin receptor chemokine receptors free fatty acid receptors hydroxycarboxylic acid receptors lysophosphatidic acid receptors oxoglutarate receptor succinate receptor |
|
|